Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.45 +0.3%	$0.48	$0.22 ▼ $3.00	$4.71M	1.02	3.05 million shs	1.12 million shs
HOOK HOOKIPA Pharma	$1.14	$1.38	$0.72 ▼ $6.68	$13.90M	0.89	82,930 shs	185,284 shs
LEXX Lexaria Bioscience	$0.95 +8.7%	$0.96	$0.79 ▼ $4.38	$18.49M	0.79	147,787 shs	392,266 shs
NEUP Neuphoria Therapeutics	$7.45 -0.5%	$6.66	$2.12 ▼ $12.55	$14.01M	0.5	35,184 shs	12,813 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	+17.19%	+88.79%	-34.23%	-57.83%
HOOK HOOKIPA Pharma	0.00%	-4.20%	-12.64%	+47.42%	-82.43%
LEXX Lexaria Bioscience	0.00%	+7.33%	-5.45%	-31.49%	-67.17%
NEUP Neuphoria Therapeutics	0.00%	-3.12%	+12.54%	+44.94%	+744,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	2.1615 of 5 stars	3.8	2.0	1.1	0.0	1.3
HOOK HOOKIPA Pharma	2.8939 of 5 stars	3.2	5.0	1.8	1.7	0.6
LEXX Lexaria Bioscience	1.7932 of 5 stars	3.5	2.0	0.3	1.7	0.6
NEUP Neuphoria Therapeutics	1.3153 of 5 stars	3.5	0.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.50	Strong Buy	$8.00	1,673.05% Upside
HOOK HOOKIPA Pharma	2.33	Hold	$4.50	294.74% Upside
LEXX Lexaria Bioscience	3.00	Buy	$5.00	428.82% Upside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	181.88% Upside

Current Analyst Ratings Breakdown

Latest ADIL, LEXX, HOOK, and NEUP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/1/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$0.64 per share	N/A
HOOK HOOKIPA Pharma	$43.95M	0.32	N/A	N/A	$4.25 per share	0.27
LEXX Lexaria Bioscience	$615.92K	30.02	N/A	N/A	$0.26 per share	3.64
NEUP Neuphoria Therapeutics	$15.66M	0.89	N/A	N/A	$15.85 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$13.20M	-$1.46	N/A	N/A	N/A	N/A	-218.88%	-177.61%	8/12/2025 (Estimated)
HOOK HOOKIPA Pharma	-$43.50M	-$5.85	N/A	N/A	N/A	-785.66%	-120.09%	-77.14%	8/6/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.67	N/A	N/A	N/A	-1,849.19%	-157.22%	-133.69%	N/A
NEUP Neuphoria Therapeutics	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/29/2025 (Estimated)

Latest ADIL, LEXX, HOOK, and NEUP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	HOOK HOOKIPA Pharma	-$0.64	N/A	N/A	N/A	N/A	N/A
8/12/2025	N/A	ADIL Adial Pharmaceuticals	-$0.25	N/A	N/A	N/A	N/A	N/A
7/14/2025	Q3 2025	LEXX Lexaria Bioscience	-$0.15	-$0.21	-$0.06	-$0.21	$0.17 million	$0.17 million
5/20/2025	Q3 2025	NEUP Neuphoria Therapeutics	-$0.47	$6.55	+$7.02	$6.55	N/A	$15.00 million
5/15/2025	Q1 2025	HOOK HOOKIPA Pharma	-$0.61	-$1.23	-$0.62	-$1.23	$3.38 million	N/A
5/14/2025	Q1 2025	ADIL Adial Pharmaceuticals	-$0.50	-$0.34	+$0.16	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HOOK HOOKIPA Pharma	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	1.99	1.99
HOOK HOOKIPA Pharma	N/A	3.61	3.61
LEXX Lexaria Bioscience	N/A	3.90	4.24
NEUP Neuphoria Therapeutics	N/A	11.01	11.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
HOOK HOOKIPA Pharma	63.88%
LEXX Lexaria Bioscience	13.06%
NEUP Neuphoria Therapeutics	15.90%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	4.26%
HOOK HOOKIPA Pharma	3.30%
LEXX Lexaria Bioscience	26.40%
NEUP Neuphoria Therapeutics	0.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	10.44 million	9.99 million	No Data
HOOK HOOKIPA Pharma	160	12.19 million	11.79 million	Optionable
LEXX Lexaria Bioscience	7	19.56 million	14.40 million	Not Optionable
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A

ADIL, LEXX, HOOK, and NEUP Headlines

Recent News About These Companies

Dementia Associated with Alzheimer’s Disease Drug Development Surges with 180+ Companies Pushing New Therapeutic Frontiers | DelveInsight

July 17 at 2:51 PM | finance.yahoo.com

NEUP Neuphoria Therapeutics Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Neuphoria Therapeutics Inc. (NEUP) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025 | globenewswire.com

Neuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business Updates

May 21, 2025 | finanznachrichten.de

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025 | globenewswire.com

Neumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

Neuphoria Therapeutics provides review of 2024, highlights 2025 plans

April 16, 2025 | markets.businessinsider.com

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

April 15, 2025 | globenewswire.com

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

March 3, 2025 | globenewswire.com

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

February 12, 2025 | globenewswire.com

Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going

February 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL, LEXX, HOOK, and NEUP Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.45 +0.00 (+0.27%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.45 0.00 (-0.27%)

As of 07/18/2025 07:58 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

HOOKIPA Pharma NASDAQ:HOOK

$1.14 0.00 (0.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.18 +0.04 (+3.51%)

As of 07/18/2025 07:58 PM Eastern

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Lexaria Bioscience NASDAQ:LEXX

$0.95 +0.08 (+8.68%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.93 -0.01 (-1.32%)

As of 07/18/2025 07:43 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Neuphoria Therapeutics NASDAQ:NEUP

$7.45 -0.04 (-0.53%)

As of 07/18/2025 03:55 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time